Sunil Gupta1, Kei Woldendorp1, Kavitha Muthiah2, Desiree Robson3, Roslyn Prichard3, Peter S Macdonald2, Anne M Keogh2, Eugene Kotlyar3, Andrew Jabbour4, Kumud Dhital1, Emily Granger3, Phillip Spratt3, Paul Jansz3, Christopher S Hayward5. 1. Heart Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Australia; Faculty of Medicine, The University of New South Wales, Sydney, Australia. 2. Heart Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Australia; Faculty of Medicine, The University of New South Wales, Sydney, Australia; Faculty of Medicine, Victor Chang Cardiac Research Institute, Sydney, Australia. 3. Heart Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Australia. 4. Heart Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Australia; Faculty of Medicine, Victor Chang Cardiac Research Institute, Sydney, Australia. 5. Heart Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Australia; Faculty of Medicine, The University of New South Wales, Sydney, Australia; Faculty of Medicine, Victor Chang Cardiac Research Institute, Sydney, Australia. Electronic address: cshayward@stvincents.com.au.
Abstract
BACKGROUND: New generation continuous-flow left ventricular assist devices (LVADs) utilise centrifugal pumps. Data concerning their effect on patient haemodynamics, ventricular function and tissue perfusion is limited. We aimed to document these parameters following HeartWare centrifugal continuous-flow LVAD (HVAD) implantation and to assess the impact of post-operative right heart failure (RHF). METHODS: We reviewed 53 consecutive patients (mean age 49.5 ± 14.1 yrs) with HVAD implanted in the left ventricle, at St. Vincent's Hospital, Sydney, between January 2007 and August 2012. Available paired right heart catheterisation (n=35) and echocardiography (n=39) data was reviewed to assess response of invasive haemodynamics and ventricular function to LVAD support. RESULTS: A total of 28 patients (53%) were implanted from interim mechanical circulatory support. Seventeen patients (32%) required short-term post-implant veno-pulmonary artery extracorporeal membrane oxygenation. At 100 ± 61 days post-implant, mean pulmonary artery pressure and mean pulmonary capillary wedge pressure decreased from 38.8 ± 7.7 to 22.9 ± 7.7 mmHg and 28.3 ± 6.4 to 13.4 ± 5.4 mmHg respectively (p<0.001). LV end diastolic diameter decreased from 71.3 ± 12.7 to 61.1 ± 13.7 mm and LV end-systolic diameter from 62.7 ± 12.3 to 53.9 ± 14.4mm (p<0.001). Aortic regurgitation remained trivial. Serum sodium increased from 133.3 ± 5.7 to 139.3 ± 2.8 mmol/L and creatinine decreased from 109.1 ± 42.5 to 74.3 ± 26.2 μmol/L (p<0.001). Across the entire cohort, the six-month survival/transplant rate was significantly lower for RHF patients (72.2%, n=18) compared to those without (96.9%, n=35, p=0.01). CONCLUSIONS: HVAD support improves haemodynamics, LV dimensions and renal function. Following implantation with a centrifugal continuous-flow LVAD, RHF remains a significant risk with a tendency to worse outcomes in the short to medium term. Crown
BACKGROUND: New generation continuous-flow left ventricular assist devices (LVADs) utilise centrifugal pumps. Data concerning their effect on patient haemodynamics, ventricular function and tissue perfusion is limited. We aimed to document these parameters following HeartWare centrifugal continuous-flow LVAD (HVAD) implantation and to assess the impact of post-operative right heart failure (RHF). METHODS: We reviewed 53 consecutive patients (mean age 49.5 ± 14.1 yrs) with HVAD implanted in the left ventricle, at St. Vincent's Hospital, Sydney, between January 2007 and August 2012. Available paired right heart catheterisation (n=35) and echocardiography (n=39) data was reviewed to assess response of invasive haemodynamics and ventricular function to LVAD support. RESULTS: A total of 28 patients (53%) were implanted from interim mechanical circulatory support. Seventeen patients (32%) required short-term post-implant veno-pulmonary artery extracorporeal membrane oxygenation. At 100 ± 61 days post-implant, mean pulmonary artery pressure and mean pulmonary capillary wedge pressure decreased from 38.8 ± 7.7 to 22.9 ± 7.7 mmHg and 28.3 ± 6.4 to 13.4 ± 5.4 mmHg respectively (p<0.001). LV end diastolic diameter decreased from 71.3 ± 12.7 to 61.1 ± 13.7 mm and LV end-systolic diameter from 62.7 ± 12.3 to 53.9 ± 14.4mm (p<0.001). Aortic regurgitation remained trivial. Serum sodium increased from 133.3 ± 5.7 to 139.3 ± 2.8 mmol/L and creatinine decreased from 109.1 ± 42.5 to 74.3 ± 26.2 μmol/L (p<0.001). Across the entire cohort, the six-month survival/transplant rate was significantly lower for RHF patients (72.2%, n=18) compared to those without (96.9%, n=35, p=0.01). CONCLUSIONS: HVAD support improves haemodynamics, LV dimensions and renal function. Following implantation with a centrifugal continuous-flow LVAD, RHF remains a significant risk with a tendency to worse outcomes in the short to medium term. Crown
Authors: Michał Zakliczyński; Jerzy Pacholewicz; Izabela Copik; Marcin Maruszewski; Tomasz Hrapkowicz; Roman Przybylski; Marian Zembala Journal: Kardiochir Torakochirurgia Pol Date: 2018-03-28
Authors: Mitra K Nadim; Lui G Forni; Azra Bihorac; Charles Hobson; Jay L Koyner; Andrew Shaw; George J Arnaoutakis; Xiaoqiang Ding; Daniel T Engelman; Hrvoje Gasparovic; Vladimir Gasparovic; Charles A Herzog; Kianoush Kashani; Nevin Katz; Kathleen D Liu; Ravindra L Mehta; Marlies Ostermann; Neesh Pannu; Peter Pickkers; Susanna Price; Zaccaria Ricci; Jeffrey B Rich; Lokeswara R Sajja; Fred A Weaver; Alexander Zarbock; Claudio Ronco; John A Kellum Journal: J Am Heart Assoc Date: 2018-06-01 Impact factor: 5.501
Authors: P Aigner; M Schweiger; K Fraser; Y Choi; F Lemme; N Cesarovic; U Kertzscher; H Schima; M Hübler; M Granegger Journal: Ann Biomed Eng Date: 2019-11-18 Impact factor: 3.934
Authors: Mojgan Ghodrati; Alexander Maurer; Thomas Schlöglhofer; Thananya Khienwad; Daniel Zimpfer; Dietrich Beitzke; Francesco Zonta; Francesco Moscato; Heinrich Schima; Philipp Aigner Journal: Artif Organs Date: 2020-05-06 Impact factor: 3.094
Authors: Peng Fang; Jianjun Du; Andrea Boraschi; Silvia Bozzi; Alberto Redaelli; Marianne Schmid Daners; Vartan Kurtcuoglu; Filippo Consolo; Diane de Zélicourt Journal: Front Cardiovasc Med Date: 2022-03-11
Authors: Mi Ok Kim; Audrey Adji; Michael F O'Rourke; Alberto P Avolio; Peter Smielewski; John D Pickard; Marek Czosnyka Journal: J Hypertens Date: 2015-06 Impact factor: 4.844